Clinilabs Selected for a Phase I Study in Patients with Obstructive Sleep Apnea
Clinilabs
, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced that they have been selected to conduct a Phase I clinical research study of an investigational medication in patients with Obstructive Sleep Apnea (OSA).
Clinilabs has been involved in clinical research related to the development of sleep therapeutics for 20 years. Barbara Smallwood, Vice President of Business Development, states “We are proud to continue our part in the search for new treatments for sleep disorders, and we look forward to assessing the effects of an investigational new drug on patients with OSA.”
Enrollment for this study is expected to begin in April 2011. Referrals from physicians and other healthcare providers are welcomed. Individuals in the New York City Metro area who have been diagnosed with OSA can contact our call center at 212-994-4567 to prequalify. Additional information may also be found by visiting
www.clinilabs.com/OSA
.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
